References
1. Bernstein JA, Singh U, Rao MB,
Berendts K, Zhang X, Mutasim D. Treatment of chronic spontaneous
urticaria with benralizumab: Report of primary endpoint per-protocol
analysis and exploratory endpoints. Allergy.2021;76(4):1277-1280.
2. Bernstein JA, Singh U, Rao MB, Berendts K, Zhang X, Mutasim D.
Benralizumab for Chronic Spontaneous Urticaria. N Engl J Med.2020;383(14):1389-1391.
3. Gimenez-Arnau A, Curto-Barredo L, Nonell L, et al. Transcriptome
analysis of severely active chronic spontaneous urticaria shows an
overall immunological skin involvement. Allergy.2017;72(11):1778-1790.
4. Ghosh D, Ding L, Sivaprasad U, et al. Multiple Transcriptome Data
Analysis Reveals Biologically Relevant Atopic Dermatitis Signature Genes
and Pathways. PLoS One. 2015;10(12):e0144316.
5. Ghosh D, Ding L, Bernstein JA, Mersha TB. The Utility of Resolving
Asthma Molecular Signatures Using Tissue-Specific Transcriptome Data.G3 (Bethesda). 2020;10(11):4049-4062.
6. Murakami M, Taketomi Y. Secreted phospholipase A2 and mast cells.Allergol Int. 2015;64(1):4-10.
7. Lopez-Dee Z, Pidcock K, Gutierrez LS. Thrombospondin-1: multiple
paths to inflammation. Mediators Inflamm. 2011;2011:296069.
8. Chaves de Souza JA, Nogueira AV, Chaves de Souza PP, et al. SOCS3
expression correlates with severity of inflammation, expression of
proinflammatory cytokines, and activation of STAT3 and p38 MAPK in
LPS-induced inflammation in vivo. Mediators Inflamm.2013;2013:650812.
Table-1. Significantly enriched disease-relevant and
treatment-relevant biological processes. (A) Processes associated with
CSU lesional skin (compared to non-lesional skin) identified by
enrichment analysis. Gene Ontology identifiers are shown within
parentheses. Top significant processes have been shown with eosinophil
chemotaxis (GO:0048245) and eosinophil migration (GO:0072677) were the
two significant (adj. p-value = 2.016e-7 for both) biological processes
associated with CSU that showed highest combined scores in enrichment
analysis. (B) Processes associated with skin transcriptomes before vs.
after benralizumab therapy.